Lusong Luo, Ph.D., is Senior Vice President & Head of External Innovation, and one of BeiGene’s founding scientists. Prior to joining BeiGene in 2010, Dr. Luo was Senior Director of Discovery Biology at BioDuro. In addition to his current role at BeiGene, Dr. Luo serves as the acting CEO and President of MapKure, LLC, a clinical-stage precision medicines company jointly owned by BeiGene, SpringWorks Therapeutics and other investors, as well as a board member of MapKure and Boston Immune Technologies & Therapeutics, a BeiGene-partnered company. Dr. Luo previously held positions at BioDuro, a contract research, development and manufacturing organization (“CRDMO”), as Senior Director and Director of Discovery Biology; and GlaxoSmithKline Oncology CEDD, where he served as Group Manager, Research Investigator, and Principal Scientist. Dr. Luo was a key member of a number of teams that have contributed to the discovery and development of more than a dozen oncology clinical compounds, five of which have obtained regulatory approvals. Dr. Luo has published more than 60 research papers, reviews, and book chapters. He trained with Professor Christopher T. Walsh at Harvard Medical School and obtained his Ph.D. in biochemistry from the University of New Mexico.